001     142209
005     20240229105147.0
024 7 _ |a 10.1164/rccm.201708-1707OC
|2 doi
024 7 _ |a pmid:29617574
|2 pmid
024 7 _ |a 0003-0805
|2 ISSN
024 7 _ |a 1073-449X
|2 ISSN
024 7 _ |a 1535-4970
|2 ISSN
024 7 _ |a 2376-3752
|2 ISSN
024 7 _ |a altmetric:35724376
|2 altmetric
037 _ _ |a DKFZ-2019-00023
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Yamauchi, Yoshikane
|b 0
245 _ _ |a Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
260 _ _ |a New York, NY
|c 2018
|b American Thoracic Society
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660215846_9237
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Myeloid-derived suppressor cell (MDSC) expansion has been found to play a role in disease progression in patients with cancer. However, the characteristics of MDSCs in lung cancer are poorly understood.We prospectively investigated MDSCs and inflammatory factors in tumor and peripheral blood samples from patients with resectable non-small cell lung cancer and studied their correlations with the disease prognosis.A complex analysis of MDSC subsets and inflammatory mediators was performed using flow cytometry and a Bio-Plex assay.A significant increase in the frequency of circulating monocytic (M)-MDSCs was observed in the patients with non-small cell lung cancer compared with the healthy donors (HDs). Moreover, the frequencies of M- and polymorphonuclear (PMN)-MDSCs were higher in tumors than in the peripheral blood of the same patients. This accumulation was associated with elevated concentrations of inflammatory mediators involved in MDSC migration to and activation in the tumor microenvironment. An analysis of the MDSC immunosuppressive pattern showed increased programmed death-ligand 1 expression on circulating cells from patients compared with HDs. Tumor PMN-MDSCs displayed higher programmed death-ligand 1 expression levels than the same cells in the peripheral blood. The frequency of CCR5 (C-C chemokine receptor 5) expression on circulating M-MDSCs was significantly higher in the patients than in the HDs. Clinical data analysis revealed negative correlations between recurrence-free survival and the frequencies of PMN-MDSCs and CCR5+ M-MDSCs in the circulation but not in tumors.Our findings suggest that the level of MDSCs in the peripheral blood but not in tumor tissues predicts recurrence after surgery.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Safi, Seyer
|b 1
700 1 _ |a Blattner, Carolin
|0 P:(DE-He78)b7546a1fc8db4a83afc82a8bbd01e52b
|b 2
|u dkfz
700 1 _ |a Rathinasamy, Anchana
|0 P:(DE-He78)a4d37cf08789986f17ff6ceb579e396e
|b 3
|u dkfz
700 1 _ |a Umansky, Ludmila
|0 P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45
|b 4
|u dkfz
700 1 _ |a Juenger, Simone
|b 5
700 1 _ |a Warth, Arne
|b 6
700 1 _ |a Eichhorn, Martin
|b 7
700 1 _ |a Muley, Thomas
|b 8
700 1 _ |a Herth, Felix J F
|b 9
700 1 _ |a Dienemann, Hendrik
|b 10
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 11
|u dkfz
700 1 _ |a Beckhove, Philipp
|0 P:(DE-He78)1732377f6242a18280bc6aaa196988d1
|b 12
|u dkfz
700 1 _ |a Utikal, Jochen
|0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|b 13
|u dkfz
700 1 _ |a Hoffmann, Hans
|b 14
700 1 _ |a Umansky, Viktor
|0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
|b 15
|e Last author
|u dkfz
773 _ _ |a 10.1164/rccm.201708-1707OC
|g Vol. 198, no. 6, p. 777 - 787
|0 PERI:(DE-600)1468352-0
|n 6
|p 777 - 787
|t American journal of respiratory and critical care medicine
|v 198
|y 2018
|x 1535-4970
909 C O |p VDB
|o oai:inrepo02.dkfz.de:142209
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)b7546a1fc8db4a83afc82a8bbd01e52b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)a4d37cf08789986f17ff6ceb579e396e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)1732377f6242a18280bc6aaa196988d1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Translational cancer research
|x 0
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J RESP CRIT CARE : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b AM J RESP CRIT CARE : 2017
920 1 _ |0 I:(DE-He78)D015-20160331
|k D015
|l Translationale Immunologie
|x 0
920 1 _ |0 I:(DE-He78)G300-20160331
|k G300
|l KKE Dermatoonkologie
|x 1
920 1 _ |0 I:(DE-He78)G160-20160331
|k G160
|l Neuroimmunologie und Hirntumorimmunologie
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D015-20160331
980 _ _ |a I:(DE-He78)G300-20160331
980 _ _ |a I:(DE-He78)G160-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21